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Abstract
Background: Multiple HIV-1 intersubtype recombinants have been identified in human populations. Previous
studies from our lab group have shown that the epidemic in Argentina is characterized by the high prevalence of
a circulating recombinant form, CRF12_BF, and many related BF recombinant forms. In these genomic structures a
recombination breakpoint frequently involved the vpu coding region. Due to the scarce knowledge of Vpu
participation in the virion release process and its impact on pathogenesis and of the functional capacities of
intersubtype recombinant Vpu proteins, the aim of this work was to perform a comparative analysis on virion
release capacity and relative replication capacity among viral variants harboring either a BF recombinant Vpu or a
subtype B Vpu.
Results: Our results showed that BF recombinant Vpu was associated to an increased viral particles production
when compared to WT B variant in tetherin-expressing cell lines. This observation was tested in the context of a
competition assay between the above mentioned variants. The results showed that the replication of the BF Vpu-
harboring variant was more efficient in cell cultures than subtype B, reaching a higher frequency in the viral
population in a short period of time.
Conclusion: This study showed that as a result of intersubtype recombination, a structurally re-organized HIV-1
Vpu has an improved in vitro capacity of enhancing viral replication, and provides evidence of the changes
occurring in this protein function that could play an important role in the successful spread of intersubtype
recombinant variants.
Background
Multiple HIV-1 intersubtype recombinants have been
identified in human populations. To date, more than 40
circulating recombinant forms (CRFs) have been
described (Los Alamos HIV Database). In South Ameri-
can countries such as Argentina and Brazil, the epi-
demic shows considerable diversity in terms of subtypes
and CRFs. Previous studies from our lab group have
shown that Argentina is characterized by the co-circula-
tion of intersubtype recombinants, mainly BF [1-7] and
subtype B viruses. Nucleotide sequence analyses showed
that HIV-1 BF recombinants exhibit diverse mosaic
structures and that the prototypic CRF12_BF genome
mainly corresponds to subtype F1 with five segments of
subtype B distributed all along the genome [1,5,6]. In
these genomic structures a recombination breakpoint
frequently involved the vpu coding region. The resulting
recombinant protein structure exhibits a subtype B
membrane-spanning domain and a- helix I, and a sub-
type F1 a- helix II.
Regarding protein functions, two distinct biological
activities have been attributed to Vpu: a) proteasomal
degradation of CD4, and b) enhancement of virion release
from infected cells. Although the mechanism by which
Vpu degrades CD4 is well delineated [8-10], its enhancing
effect on virion release is not fully clarified. It was shown
that the transmembrane domain of the protein forms
cation-selective ion channels in cellular membranes and
that this feature might be involved in facilitating virion
release [11,12]. Nevertheless, recent studies have shown
that Vpu-dependent virion release is related to its capacity
to counteract an INFa-inducible host restriction factor
known as Bst-2/CD317/tetherin [13-15].
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Since data on Vpu participation in the virion release
process and its impact on pathogenesis is still incom-
plete and scarce, and on account of the remarkable pro-
tein diversity, and that most studies have been
conducted on Vpu protein from subtypes B or C, the
present study was aimed at analyzing the virion release
capacity of a naturally occurring BF recombinant Vpu,
and its comparison with its pure subtype B counterpart.
A chimeric variant harboring a naturally occurring BF
recombinant vpu coding sequence on a subtype B
genetic background (NL4-3) was generated and used for
the studies. Our results show that the BF recombinant
Vpu is capable of enhancing virion release more effi-
ciently, suggesting an improvement in this function as a
consequence of an intersubtype recombination event.
Results
Structural characterization of naturally occurring BF
intersubtype recombinant Vpu sequences
A previous study from our lab group found a high per-
centage of BF recombinant strains (56.9%, n = 283)
among drug-naïve newly diagnosed HIV-1 individuals
[7]. When re-analyzing this group of samples we found
that 109 out of 161 (67.7%) of these recombinant var-
iants exhibited a recombination pattern which involved
the vpu coding region. The analysis of these sequences
was performed by means of a tool to detect HIV-1
genomic recombinants available online at http://jphmm.
gobics.de/, and confirmed by bootscaning analysis (Sim-
plot V3.5.1). Seventy four (68.3%) sequences presented a
very similar recombination pattern to that observed in
CRF12_BF, where the breakpoint was located between
positions 6195 and 6205 of the genomic sequence,
according to the HXB2 numbering.
A naturally occurring BF recombinant was selected
for the biological analysis. This variant, named
CRF12_BF-like, was chosen because it shares a similar
recombination pattern to that observed in the prototypic
CRF12_BF [1] (Figure 1A) where the membrane-span-
ning domain and the a-helix I intracytoplasmic domain
(positions 1-50), and the a-helix II together with the 10
C-terminal aminoacids (positions 51-81) correspond to
subtypes B and F1 respectively. Comparison of its pri-
mary amino acid sequences (CRF12_BF vs. CRF12_BF-
like) showed that only 9 out of 81 residues (11.1%) differ
from each other, i.e. T6I, A22V, S24T, I43L, E58D,
F67L, E69D, L72P, and N80I (Figure 1B). An additional
analysis performed on 74 recombinant sequences
showed that these substitutions did not occur as inher-
ent features of the selected CRF12_BF-like variant. Even
more, some of them were highly represented among the
naturally occurring recombinants.
A serine residue, either at position 61 or 64 (S61 or
S64) has been shown to be involved in the regulation of
Vpu degradation process [16]. Neither S61 nor S64 were
present in the CRF12_BF-like variant. Additionally, the
analysis of B (n = 137), F1 (n = 12) and BF recombinant
(n = 120) Vpu sequences (Los Alamos Database) from
Argentina, Brazil, and Uruguay showed that S64 was
present in 82% and 6.6% of B and BF sequences respec-
tively. This residue was not found among F1 sequences.
None of the whole set of sequences harbored the S61
residue.
The comparative analysis of Vpu amino acid
sequences performed among the variants used in this
work, in terms of protein domains, is shown in Table 1.
Most of the differences were found in the a-helix II and
C-terminal domains. Of note, net charge of these
domains differed among variants. BF has + 4 and - 5
charges in the a-helix I and a-helix II respectively, com-
pared to the + 3 and - 4 charges found in the subtype B
variant. The net charge of C-terminal domains remained
constant (-1) although amino acid changes were found.
Functional analysis of BF intersubtype recombinant Vpu
vpu mRNA is correctly synthesized from the BF Vpu
harboring-chimeric variant
A chimeric viral genome, named pNL4-3 VpuBF, har-
boring the CRF12_BF-like Vpu sequence on a pure sub-
type B (NL4-3) background (Figure 1C), was generated
to evaluate the consequences of intersubtype recombina-
tion involving the vpu coding region on viral particles
release enhancement.
In order to test the vpu mRNA expression, HeLa cell
cultures were transfected either with pNL4-3 VpuBF,
pNL4-3 VpuB and pNL4-3 ΔVpu plasmids. Forty eight
hours post-transfection total mRNA content was
obtained from each transfected culture, and vpu mRNA
production was evaluated by qualitative RT-PCR. b-
actin mRNA was used as control. All transfected cell
cultures exhibited comparable expression levels of vpu
mRNA (Figure 2).
BF Vpu correlates with an increased viral release in
Vpu-dependent cell line models
This study was aimed at evaluating the impact of BF
recombinant Vpu on viral release by transfecting both
HeLa and 293T cell lines with pNL4-3 VpuBF, pNL4-3
VpuB and pNL4-3 ΔVpu. As previously described, HIV-
1 Vpu is essential for viral replication in certain cell
lines (e.g. HeLa) but dispensable in others (e.g. 293T)
[13-15,17]. Viral production was monitored by quantify-
ing p24 antigen in cell culture supernatants 24 and 48 h
post-transfection.
In HeLa cells, transfection with pNL4-3 VpuBF
resulted in a substantially higher p24 antigen concentra-
tion in culture supernatant when compared with that of
the subtype B counterpart and ΔVpu, at 24 h post-
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Figure 1 Structural analysis of BF intersubtype recombinant Vpu (A and B) and schematic representation of chimeric viral genome
construction (C) A. Comparison of bootscaning analysis performed on CRF12_BF and CRF12_BF-like showed a similar recombination pattern,
with a breakpoint located between a-helix I and II. Reference sequences of subtype B (red), F (black), and A (blue) - out group - were obtained
from Los Alamos Database. Plots represent bootstrap values based on 100 re-samplings, supporting branching with reference sequences within a
140 nt window moving in steps of 20 bases. The structural domains as well as the phosphorylation sites (asterisks) of Vpu are shown in Figure
1B. Underlined residues represent differences between CRF12_BF and CRF-like variant. C. Diagram depicts the construction step of a chimeric
viral genome: vpu coding sequence from a naturally occurring BF intersubtype recombinant variant (named CRF12_BF-like) amplified by PCR
from a genomic DNA sample obtained from an infected patient. The use of modified oligonucleotides allowed the introduction of both PacI
and Eco47III restriction sites. The purified PCR product was cloned into a commercial vector (pGEM-T) to obtain the pVpuBF plasmid. In parallel,
these restriction sites were introduced in pNL4-3 by PCR-based site-directed mutagenesis. After digestion and ligation steps a chimeric variant
harboring the Vpu BF sequence into the subtype B genomic background (pNL4-3 VpuBF) was obtained.
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transfection (22.5 pg/ml, 4.9 pg/ml and 0.4 pg/ml
respectively). This difference persisted after 48 h post-
transfection (114.7 pg/ml vs. 25.6 pg/ml), showing an
approximately 4.5-fold increase in p24 production when
the intersubtype recombinant protein was present
(Figure 3A).
The evaluation of post-transfection viral production in
293T cell cultures with the variants studied showed no
significant differences in the p24 content of culture
supernatants (Figure 3B), confirming that both pNL4-3
and pNLVpuBF promoted viral release with similar effi-
ciency in this Vpu-independent cell model.
Viral release was also evaluated in Jurkat and CEM-
GFP cell lines, both known to constitutively express
tetherin [13,18] and representing Vpu-dependent mod-
els. As described in the Materials and Methods section,
Jurkat and CEM-GFP cell cultures were infected with
each viral stock (NL4-3 VpuBF, NL4-3 VpuB, NL4-3
ΔVpu), and viral production kinetics was evaluated by
quantitation of virus-associated RT activity in culture
supernatants. After 24 h, comparable levels of infection
were achieved for each virus in both Jurkat and CEM-
GFP cell cultures, evaluated as percentage of p24 (+) or
GFP-expressing cells (FACS) respectively (data not
shown).
Viral production was significantly higher for the NL4-
3 VpuBF in both Jurkat and CEM-GFP cell cultures
(1.5-fold and 1.8-fold respectively), when compared to
the wild type variant (Figures 3C and 3D).
Relative in vitro replication capacity
The relative replication capacity of WT subtypes B and
chimeric BF variants was tested in vitro by performing a
competitive dual infection. Both variants were used to
infect CEM-GFP cell culture, in duplicate, and main-
tained up to 21 days post-infection (p.i.). Viral popula-
tion analysis was performed on days 1, 12 and 21 p.i. by
cloning and sequencing the vpu coding region, as
described in the Material and Methods section. Of note,
subtype B sequences were predominant at the beginning
(B/BF ratio: 1.52) but its ratio changed over time; the
recombinant variant became more frequent (B/BF ratio:
0.99) at the end of the experiment. B/BF variants ratio
at each time point is depicted in Figure 4.
Discussion
The vpu coding sequence is one of the most variable
regions of the HIV-1 genome [19]. It is unknown if this
variability and the diversity among different HIV-1 sub-
types [20] may have an effect on protein functions, and
to what extent this effect may have an impact on HIV-1
transmission and pathogenecity.
A recent report has shown that only HIV-1 strains
from the M group express a fully functional Vpu protein
and the authors postulate that this may explain the glo-
bal HIV/AIDS pandemic for the HIV-1 M group [21].
However, most of the structural and functional studies
on Vpu have been performed on subtype B proteins.
Hence, little is known about the functionality of non-
subtype B Vpu, not even about its function as a viral
release enhancer. In this work we performed a compara-
tive analysis between subtype B and BF intersubtype
recombinant Vpu proteins, focusing on this important
function.
The structural analysis carried out on naturally occur-
ring BF recombinant Vpu sequences revealed high con-
servation of the recombination pattern. This pattern was
Table 1 Comparative analysis of amino acid differences between subtype B and CRF12_BF-like variants. Positions are
shown according to protein domains.
N-Terminal Transmembrane a-Helix I
Positions 3 4 5 7 16 18 24 27 43 46 47
Subtype B P - I V I I S I I L I
CRF12_BF-like S L V L A L T L L I R
a-Helix II C-Terminal
Positions 58 60 61 62 63 65 66 67 68 69 70 73 74 75 77 78 81
Subtype B E E V S A V E M G V E H H A W D D
CRF12_BF-like D D A E E A A - L G G P L I G N I
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Figure 2 Vpu expression was assessed by specific RT-PCR of
vpu mRNA after transfection of HeLa cells. Both untransfected
(UT) cells and cells transfected with empty vector (NC) were used as
control (right panel). Amplification of b-actin mRNA was also
evaluated as an internal control (left panel).
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similar to that observed in the prototypic BF recombi-
nant, CRF12_BF, where the breakpoint is located in the
region coding for an amino acid stretch predicted to
form a random-coil structure [20]. This region contains
two serine residues (S52 and S56), targeted by the casein
kinase II, which phosphorylation is an essential step in
recruiting the b-TrCP complex and subsequent protea-
some-mediated degradation of CD4 [10,22,23]. Recent
studies suggest that Vpu may induce internalization and
degradation of tetherin by the same pathway [18,24,25].
On the other hand, Vpu degradation is accomplished
through a b-TrCP independent mechanism that involves
phosphorylation of a serine residue at position 61 or 64.
Lack of these residues has been shown to increase the
protein stability without affecting the CD4 degradation
[16,26]. We have found that S61 was absent in the
CRF12_BF and all related BF recombinant Vpu
sequences, and that only 6.6% of them presented the S64
residue. Neither CRF12_BF nor the CRF12_BF-like var-
iant harbored S61 or S64, which might suggest that the
turnover of the recombinant variants could be different
from the pure subtype counterpart, partly explaining at
least the higher viral release associated to the former.
It has been shown that an intact transmembrane
domain of HIV-1 Vpu is important and sufficient to
enhance HIV-1 particle release [12,27]. This domain is a
critical determinant of its function since it physically
interacts with the BST-2 transmembrane domain leading
to its degradation [28,29]. As determined by the com-
parative analysis of Vpu amino acid sequences per-
formed in this work, 5 amino acid changes were found
between the variants studied, and all of the substitutions
were conservative, i.e. amino acids belonging to the
same chemical group, suggesting a consequent func-
tional conservation of this domain.
Our results showed that BF Vpu increased viral par-
ticles production when compared to the WT B variant
in tetherin-expressing cell models. As shown in the
results obtained from the in vitro competition assay,
this difference in viral production might represent an
advantage for the virus in terms of replication capacity
or fitness.
According to the structural characteristics of the recom-
binant protein, the interchange of the second half of the
Vpu coding sequence, encompassing the a-helix II and
the C-terminal segment between subtypes B and F1, may
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Figure 3 HeLa (A) and 293T cells (B) were transfected with plasmids pNL4-3 VpuB, pNL4-3 Vpu BF, and pNL4-3 ΔVpu, separately. Viral
production was evaluated, using an ELISA assay, by measuring the Gag p24 antigen content in cell culture supernatants 24 and 48 hours post-
transfection. Jurkat cells (C) and CEM-GFP (D) were infected with equal MOI of NL4-3 Vpu B, NL4-3 Vpu BF and NL4-3 ΔVpu virus stock, and viral
replication was monitored by measuring the virus-associated reverse transcriptase activity in culture supernatants. Error bars indicate standard
errors. Results are representative of two independent experiments.
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have resulted in an alternative protein form with enhanced
regulation capacity of the host cell environment.
Previous molecular studies from our lab group have
shown that BF intersubtype recombination frequently
affected genomic regions involved in regulating viral
gene expression, replication, and interaction with the
host immune system [30-35]. Taken together, these
results sustain the idea that this phenomenon might
have played an important role in the successful spread
of the resulting variants, arguing in favor of the inter-
subtype recombination as a powerful source of variabil-
ity and adaptation capacity.
As accessory proteins and/or their cellular counter-
parts are nowadays seen as promising future therapeutic
targets [36-39], results presented here contribute to the
comprehensive and profound knowledge of protein
functions and its variations needed to develop more
effective and specific therapeutic agents aimed at block-
ing viral replication.
Conclusion
As described above, our results show that intersubtype
recombination gave rise to a structurally re-organized
HIV-1 Vpu variant with an improved capacity of enhan-
cing viral replication, when tested in vitro. Although
these results correspond to a single recombinant isolate,
it provides evidence on the changes in the protein func-
tion that could play a role in the spread of intersubtype
recombinant variants, having implications on HIV-1
epidemiology and pathogenesis. These data are also
important in the context of future therapeutic
approaches.
Methods
Plasmids, cells and viruses
The vpu coding sequence from a naturally occurring BF
intersubtype recombinant variant (named CRF12_BF-
like) was amplified by PCR from a genomic DNA sam-
ple obtained from an infected patient identified in a pre-
vious study conducted in Argentina [7]. PCR reaction
was carried out by using a high fidelity DNA polymerase
(Platinum® Taq DNA Polymerase High Fidelity, Invitro-
gen). Oligonucleotides used for the reaction were:
VpuBF/PacI (5’-TTAATTAAGCTTCTCTATCAAA-
GC-3’)
VpuBF/Eco47III (5’-AGCGCTAAAGAAAAATTGT-
GGGTC-3’)
Modifications in the oligonucleotides allowed obtain-
ing a PCR product harboring both PacI and Eco47III
restriction sites at the 5’ and 3’ ends of the vpu coding
sequence respectively. The amplicon was subcloned into
a commercial vector (pGEM-T® easy vector, Promega)
according to the manufacturer’s instructions. The result-
ing transformants were screened for the insert and the
plasmids were sequenced to ensure that BF recombinant
vpu sequences and restriction sites were intact. The
resulting plasmid was named as pVpuBF.
Insertion of the BF vpu gene into HIV-1 molecular
clone pNL4-3 [40] (obtained from Dr Malcolm Martin
through the AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH) was accomplished
in a two-step procedure. The first step involved the
introduction of PacI and Eco47III restriction site at the
5’ and 3’ ends of the pNL4-3 vpu coding sequence
respectively, by site-directed mutagenesis. Oligonucleo-
tides used for this step were:
VpuB/PacI (5’-GCTCATCAGAACAGTCAGAT-
TAATTAAGCTTCTCTATCAAAGC-3’)
VpuB/Eco47III (5’-GGGATATTGATGATCTGTAG-
CGCTACAGAAAAATTGTGGGTC-3’)
The second step consisted in the replacement of the
WT pNL4-3 Vpu coding sequence with the CRF12_BF-
like Vpu sequence, followed by reversion of the changes
introduced to the original sequence by a new cycle of
site-directed mutagenesis. Briefly, both pNL4-3 PacI/
Eco47III and pVpuBF were digested with each restric-
tion enzyme. Ligation of the pNL4-3 PacI/Eco47III
backbone and the VpuBF PacI/Eco47III insert was per-
formed by T4 ligase (Invitrogen). Oligonucleotides used
for the site-directed mutagenesis reaction were:
VpuPacIrevt (5’-GCTCATCAGAACAGTCAGACT-
CATCAAGCTTCTCTATCAAAGC-3’)
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Figure 4 NL4-3 VpuB and NL4-3 VpuBF viruses were competed
against each other by infecting CEM-GFP reporter cells with
p24-normalized inocula at 1:1 ratio. Each variant ratio was
determined by clonal analysis of viral population present in culture
supernatants. Error bars indicate standard errors. Results are
representative of two independent experiments.
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VpuEco47IIIrevt (5’-GGGATATTGATGATCTG-
TAGTGCTACAGAAAAATTGTGGGTC-3’)
Again, the resulting transformants were screened for
the insert and any possible unwanted changes in the
generated plasmid.
Mini and midipreps of selected clones were obtained
(QIAgen).
All mutagenesis reactions were performed by using
a highly processive DNA polymerase with proofreading
3’-5’ exonuclease activity (Platinum®PfxDNA Polymerase,
Invitrogen). Sequencing was performed on an automatic
sequencer (Applied Biosystems DNA sequencer 3100)
by using the Big Dye Terminator sequencing kit (Amer-
sham, Sweden). Nucleotide sequences were analyzed
and manually adjusted using Sequencher 4.0.5 software
(Gene Codes Co, USA).
The Vpu-deficient plasmid pNL4-3 ΔVpu[41]
(obtained from Dr. Klaus Strebel through the AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH) contains a defective vpu gene, but
is otherwise identical to the infectious molecular clone
pNL4-3.
HeLa, 293T, MT2, Jurkat T and CEM-GFP cells were
used in this study. HeLa and 293T were cultured in
DMEM medium (Gibco®) supplemented with 10% fetal
bovine serum (FBS, Gibco®), 2 mM L-glutamine
(Gibco®), penicillin/streptomycin (100 IU/ml and 100
μg/ml respectively, Gibco®). MT2 and Jurkat T cells
were cultured in RPMI-1640 medium (Gibco®) supple-
mented with 10% FBS, 2 mM L-glutamine, 100 U/ml
penicillin and 100 μg/ml streptomycin. CEM-GFP cells
were cultured in the same medium plus 500 μg/ml
G418. Cell lines were obtained through the AIDS
Research and Reference Reagent Program.
293T cells transient transfections were carried out
using Lipofectamine2000 (Invitrogen) following manu-
facturer’s instructions. For single transfections experi-
ments confluent cells grown in 24-well dish were
transfected with 0.8 μg of pNL4-3 Vpu B, pNL4-3
VpuBF and pNL4-3 ΔVpu.
Viral stocks were obtained by infecting MT2 cells.
Briefly, 2×106 cells were infected with 1 ml of culture
supernatant from 293T cell culture transfections. After-
wards, cells were washed twice with PBS and maintained
in culture medium, until CPE was observed. Viral stock
titrations (TCID 50/ml values) were performed by using
the Reed and Muench method [42].
RT-PCR
HeLa cells transient transfections were carried out using
Lipofectamine2000 (Invitrogen) following manufacturer’s
instructions. For single transfections experiments conflu-
ent cells grown in 60 mm Petri dishes were transfected
with 8 μg of pNL4-3 Vpu B, pNL4-3 Vpu BF and
pNL4-3 ΔVpu. Untransfected cells as well as cells trans-
fected with empty vectors were always used as negative
controls.
Total cellular RNA was extracted from 107 cells
using Trizol® reagent (Invitrogen). Three μg of RNA
were reverse transcribed using MMLV reverse tran-
scriptase (Invitrogen) and an oligo-dT primer. The mix
was supplemented with RNAse inhibitors (Invitrogen)
in a final volume of 20 μl. Two μl of cDNA were used
for vpu PCR amplification using the following
oligonucleotides:
VpuB fw (5’-CCTCTAGATAATGCAACCTATAA-
TAG-3’);
VpuB rev (5’-CACGCGTCTACAGATCATCAA-
TATCC-3’);
VpuBF fw (5’-CCTCTAGATAATGCAATCTTTAG-3’)
and
VpuBF rev (5’-CACGCGTCTACAGAATATCAA-
TATTC-3’).
PCR amplification of b-actin, used as RNA quality
control, was performed by using the following
oligonucleotides:
b1 (5’-GGACCTGACTGACTACCTCATGAA-3’)
b2 (5’-GATCCACATCTGCTGGAAGGTGG-3’).
Vpu recombinant sequences analysis
BF recombinant Vpu sequences were obtained from Los
Alamos HIV sequence database. A multiple alignment
with reference sequences was performed using Clustal
W, and visually corrected with the BioEdit version 5.0.9
program http://www.mbio.ncsu.edu/BioEdit/bioedit.html.
Detection of intersubtype genomic recombination was
carried out by a tool available online at http://jphmm.
gobics.de. This method uses a probabilistic approach to
compare a sequence to a multiple alignment of a
sequence family [43]. Recombination analysis was con-
firmed by bootscanning analysis as implemented in the
SimPlot v.3.5.1 program.
HIV-1 production assay: transfections and infections
HeLa and 293T cells were transfected with 0.8 μg of
pNL4-3 VpuB, pNL4-3 VpuBF and pNL4-3 ΔVpu
together with 0.05 μg of GFP expression vector used as
a control for the transfection, using Lipoafectamine2000
(Invitrogen) and following manufacture’s instruction.
Cell culture supernatants were collected 24 and 48
hours post-transfection. HIV-1 p24 antigen quantitation
was performed by means of a commercial ELISA assay
(Murex, Abbott).
For viral replication kinetics analysis, 106 logarithmi-
cally growing Jurkat or CEM-GFP suspension cells were
infected in duplicate with each viral stock (NL4-3 VpuB,
NL4-3 VpuBF and NL4-3 ΔVpu) at MOI of 0.01. After-
wards, cells were washed twice with PBS and maintained
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in culture medium. Cell culture supernatants were har-
vested at different time points and assayed for RT activ-
ity, using the Reverse Transcriptase Colorimetric Assay
(Roche) following manufacture’s instruction.
Growth competition assay
Competitive growth of NL4-3 Vpu B and NL4-3 Vpu BF
viruses was analyzed as recently described [44]. Briefly,
2×106 CEM cells were infected in duplicate with wild--
type and the BF chimeric variants at a ratio 1:1. Cells
samples were collected at 3 time points (1, 12 and 21 d.
p.i.), and genomic DNA was extracted using the
QIAamp DNA Mini kit (QIAgen). Vpu coding sequence
was PCR amplified from proviral DNA with primers
ACC7 (5’-CTATGGCAGGAAGAAGCGGAGA-3’) and
ZM140E (5’-GGGGTCAACTTTACACATGGCTTT-3’).
PCR products were gel-purified (QIAquick gel extrac-
tion kit) and cloned into a commercial cloning vector
(pGEMT-EASY®, Promega). Nucleotide sequencing was
performed as described above.
Statistical analysis
All data was expressed as mean ± SD unless otherwise sta-
ted. Significance (p < 0.05) between means of experiments
was evaluated using the Student’s t test for independence
samples (Primer of Biostatistics version 4.02 software)
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